Tokyo, October 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that Astellas has terminated the discussion with the Chemo-Sero-Therapeutic Research Institute (“Kaketsuken”) with respect to the potential transfer of business.
Astellas has discussed with Kaketsuken with respect to the potential transfer of business of Kaketsuken to Astellas, but taking into the current situation and various factors, Astellas has decided to terminate the discussion with Kaketsuken.
It will not affect the existing agreement with Kaketsuken and associated business.
Astellas will continue making efforts on providing appropriate information and stable supply as a distributor of products of Kaketsuken.
